Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

The accepted standard treatment of relapsing multiple sclerosis consists of medications for
disease symptoms, including treatment for acute exacerbations. However, currently there is …

Background Interferon beta is used to modify the course of relapsing multiple sclerosis.
Despite interferon beta therapy, many patients have relapses. Natalizumab, an α 4 integrin …

The primary clinical outcome measure for evaluating multiple sclerosis in clinical trials has
been Kurtzke's expanded disability status scale (EDSS). New therapies appear to favourably …

Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at
all stages of disease, and to identify predictors and clinical correlates of GM atrophy. …

Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined
effects of treatment on neuropsychological (NP) performance. To evaluate the effects of …

Objectives: To examine the relationship between patient-reported depression and adherence
to therapy with interferon beta-lb (IFNβ-1b) and to test the hypothesis that treatment of …

Background: Brain imaging studies detect abnormalities in normal-appearing white matter
in patients with MS. Objective: To investigate the histopathologic basis for these changes in …

• Multiple sclerosis (MS) and other chronic illnesses can drastically decrease quality of life (QOL),
but there has been little systematic study of QOL in patients with chronic medical …

During the past 10 years, the intense involvement of the grey matter of the CNS in the pathology
of multiple sclerosis has become evident. On gross inspection, demyelination in the grey …